Latest Evidence on Active Surveillance Interventions
Evidence.zone is a free resource for men on active surveillance for prostate cancer. Every intervention rated by the strength of the published research — so you know what's proven, what's promising, and what's noise.
Three new interventions this week — and the most important one costs nothing.
Relationship & Intimacy (Connection) — Tier 2, Start. This card is based on research from PC-PEP (Prostate Cancer Patient Empowerment Program) — a comprehensive 6-month home-based programme developed at Dalhousie University that combines relationship and intimacy coaching, stress management, diet, exercise, and pelvic floor training for prostate cancer patients.
Their RCT, published in European Urology, showed the programme significantly reduces psychological distress in men undergoing prostate cancer treatment. PC-PEP is now being implemented internationally across Canada, New Zealand, South Africa, and Romania.
For men on AS, where anxiety is the single biggest reason men abandon surveillance for treatment they may not need, the connection component deserves its own card. Thanks to Rob Rutledge at PCPEP for the suggestion.
Also added: Berberine (Tier 3) — the most coherent preclinical story of any supplement in the library, with a proven bioavailability hack using silymarin.
Fenbendazole (Tier 3) — the veterinary dewormer with genuine lab data but zero human evidence and real safety concerns.
All cards include full study citations, limitations, and an overview.
Interested in more discussions like this? Go to the Prostate Cancer Support Group.
Connect

@paulsweeney
Paul, I wanted to ask you this.
I used to exercise a lot, testosterone levels were constantly rising. Everything was leading up to my doctor saying that if my testosterone kept rising, I'd have to have my balls amputated.
I decided to take a rather unusual approach. I actually stopped moving a lot and reduced my exercise to almost nothing. After that, my testosterone levels dropped again.
What do you think about what I wrote about the connection between testosterone levels and exercise?
I read about IGF on your website. Is it scientifically proven that it reduces the progression of prostate cancer?
Thank you, I await your reply!
@handera Alan, this is really well put — and I think you've identified something important that the review itself doesn't address.
The review holds lifestyle interventions to the standard of "durable deferral of definitive treatment" and finds the evidence insufficient. Fair enough. But as you say, the same standard applied to RALP yields 21-60% biochemical recurrence at 8 years. That's not a cure — it's a deferral with side effects.
What strikes me is the asymmetry in how we evaluate the two approaches. Lifestyle interventions are expected to prove they prevent progression before they're taken seriously. Surgery is assumed to be definitive and the burden of proof falls on anyone who questions it. But the data you've cited shows that assumption doesn't hold — a significant proportion of men who undergo surgery will face further treatment down the line, plus the near-certainty of short-term side effects and the real probability of lasting ones.
I agree with the review's finding that exercise has the strongest evidence — the ERASE trial data on PSA, cancer cell growth, and quality of life is hard to argue with. And I think the review is right to be cautious about supplements as a category. But the conclusion that lifestyle interventions provide only "supportive" benefit while treatment provides "definitive" benefit doesn't survive contact with the recurrence data you've shared.
Your "boot camp" framing is exactly right. A diagnosis isn't a death sentence — it's a signal to get serious about everything within your control. And for low-to-favourable intermediate risk, the evidence increasingly supports that an active, engaged approach to surveillance is a legitimate strategy, not just a holding pattern.
Really glad you're in this conversation.
Paul
-
Like -
Helpful -
Hug
2 ReactionsThank you for the question — it's a really important one and I want to be careful with my answer because I'm not a doctor.
On the testosterone and exercise connection: it's true that intense exercise can cause temporary spikes in testosterone. But the relationship between testosterone and prostate cancer is more complicated than "higher testosterone = worse cancer." The evidence on this has actually shifted significantly in recent years. The ERASE trial — a randomised controlled trial specifically in men on active surveillance — showed that HIIT exercise decreased PSA, decreased PSA velocity, and inhibited prostate cancer cell growth. Those men were exercising intensely three times a week. If exercise-induced testosterone was driving their cancer, you'd expect the opposite result.
The concern your doctor raised about testosterone may be specific to your clinical situation — particularly if you're being considered for androgen deprivation therapy (ADT). In that context, the goal is to suppress testosterone as low as possible, and your doctor may have been concerned about anything that works against that suppression. That's a very different situation from a man on active surveillance where the goal is to monitor, not suppress.
Stopping exercise to control testosterone worries me, because the overall evidence strongly favours exercise for men with prostate cancer — not just for cancer-specific outcomes, but for cardiovascular health, mental health, bone density (especially important if you're on ADT, which causes bone loss), and overall survival. I'd really encourage you to discuss this with your oncologist and ask specifically whether the exercise benefits outweigh the testosterone concern in your case. I suspect they will.
On IGF — you're right that evidence.zone mentions it. Insulin-like growth factor (IGF-1) is associated with prostate cancer progression in observational studies, and it's one of the reasons obesity and high-insulin diets are flagged as risk factors. But "associated with" is not the same as "proven to cause." The evidence that lowering IGF-1 through diet or lifestyle slows prostate cancer progression in humans is not yet proven in clinical trials — it's biologically plausible and supported by population-level data, but we don't have an RCT showing "lower your IGF-1 and your cancer progresses more slowly." What we do know is that the things that lower IGF-1 — plant-rich diets, healthy weight, moderate exercise, reduced dairy — are the same things that show up across the evidence base as beneficial for men with prostate cancer.
Paul
-
Like -
Helpful -
Hug
4 Reactions@denis76
While Exercise provides vital muscle-preserving benefits, it cannot override the biochemical mechanism of ADT. It can’t keep your testosterone up for more than a very short time.
Are you on the agonist version of ADT (Lupron) or the antagonist version (Firmagon, Orgovyx). Switching to the other version may be what you need to keep the testosterone down.
-
Like -
Helpful -
Hug
2 Reactions@jeffmarc
ADT still on diphereline (Triptorelin)
My doctor said that if my testosterone doesn't rise above a certain level and my PSA remains low, I shouldn't change my medications—they're both working.
Remember, my testosterone levels have dropped. Knock on wood.
@denis76
You did appear to be concerned after the rise of T when doing workouts.
Triptorelin Is an agonist so Firmagon an antagonist might not see a rise. I don’t think you have the ability to get Orgovyx the other antagonist.
As long as it’s keeping your testosterone down, you don’t need to switch, as your doctor says.
-
Like -
Helpful -
Hug
1 Reactionthank you both very much for sharing this information. I really appreciate the research and your analyses
@handera “…current evidence remains inconsistent to demonstrate a effect on biopsy grading, MRI, etc…”
Nothing works consistently on everyone - even definitive treatment fails 30% of the time for both radiation and surgery.
So why shouldn’t drastic -and they are for some people, as drastic as surgery - lifestyle changes ALSO fail 30% of the time?
Don’t get me wrong, if 70% of men could avoid treatment by doing as you have done, it would be Breaking news on CNN, but sadly it only works for some and for many others, only short term. Best,
Phil
@heavyphil
Not sure where your 30% failure rate, for definitive treatment, comes from; but the 2024 research I cited earlier indicates that the BCR rate, 8 years post RALP, varies significantly, based on biopsy determined risk category, from 21% to 60%.
I’ve heard Dr. Matt Cooperberg (UCSF) indicate that if he has a Gleason 3+3 patient decide anything other than active surveillance, he feels he has not adequately informed him of the true nature of his disease.
IMHO, under the current way of labeling “prostate cancer”, it’s two different diseases…based on risk category, regarding its life threatening nature.
That’s why I think evidence based, patient controllable interventions, are primarily for managing “low risk” PCa men, defined either as being diagnosed with Gleason 3+3 or having a low risk Decipher score.
Higher risk PCa should be actively treated, even though additional treatment(s), down the road, is(are) more likely to be needed.
What I wonder is how many men with low risk PCa go forward with active treatment and then attribute their “remission” to the active treatment, when in fact they may have done just as well….possibly many more years without potential side effects….if they had no active treatment and/or had waited until higher risk disease had been confirmed.
-
Like -
Helpful -
Hug
2 Reactions@handera
A timely comment?
This study just published yesterday!!!
“Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous”
https://jamanetwork.com/journals/jamaoncology/article-abstract/2849438
Conclusion:
“In this study, dropping the cancer label from GG1 prostate disease and redefining GG1 prostate disease as a precancerous lesion led to a net reduction in estimated prostate cancer deaths. Proponents for retaining the cancer label for GG1 prostate disease should argue relabeling would have close to zero effects on screening rates or that other harms outweigh the benefits of reduced prostate cancer mortality.”
Results: In the base case, which was relatively conservative, relabeling would lead to 6-fold more annual prostate deaths avoided than caused (2835 vs 452).
-
Like -
Helpful -
Hug
3 Reactions